Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | 23-cyclic-nucleotide 2-phosphodiesterase | 0.3335 | 0.5548 | 0.3301 |
Giardia lamblia | Hypothetical protein | 0.1363 | 0 | 0.5 |
Echinococcus multilocularis | alkaline phosphatase, intestinal, gene 2 | 0.4917 | 1 | 0.5 |
Echinococcus granulosus | intestinal type alkaline phosphatase 1 | 0.4917 | 1 | 0.5 |
Schistosoma mansoni | 23-cyclic-nucleotide 2-phosphodiesterase | 0.3325 | 0.5521 | 0.3261 |
Echinococcus multilocularis | alkaline phosphatase | 0.4917 | 1 | 0.5 |
Echinococcus granulosus | alkaline phosphatase | 0.4917 | 1 | 0.5 |
Echinococcus multilocularis | intestinal type alkaline phosphatase | 0.4917 | 1 | 0.5 |
Schistosoma mansoni | alkaline phosphatase | 0.4917 | 1 | 1 |
Echinococcus multilocularis | intestinal type alkaline phosphatase 1 | 0.4917 | 1 | 0.5 |
Echinococcus granulosus | alkaline phosphatase intestinal gene 2 | 0.4917 | 1 | 0.5 |
Schistosoma mansoni | alkaline phosphatase | 0.4917 | 1 | 1 |
Toxoplasma gondii | 5'-nucleotidase, C-terminal domain-containing protein | 0.3335 | 0.5548 | 1 |
Treponema pallidum | 5'-nucleotidase (ushA) | 0.3335 | 0.5548 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
GI (functional) | = 36 % | Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 assessed as growth inhibition at 6.25 ug/ml after 5 to 8 days by microplate alamar blue assay relative to control | ChEMBL. | 23876988 |
MIC (functional) | > 6.25 ug ml-1 | Antitubercular activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 5 to 8 days by microplate alamar blue assay | ChEMBL. | 23876988 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.